Sangamo Says Sanofi To Transition Sickle Cell Disease Program Back To Sangamo - Quick Facts

Genomic medicines company Sangamo Therapeutics, Inc. (SGMO) announced Thursday that French drug major Sanofi (SNYNF,SNY) will be transitioning its rights and obligations related to SAR445136 back to Sangamo over the first half of 2022.

SAR445136 is a zinc finger nuclease gene-edited cell therapy candidate in development by Sangamo and Sanofi for the treatment of sickle cell disease (SCD). Sanofi has elected to transition the SCD program to Sangamo following a recent change in Sanofi's cell therapy strategy.

The Companies are collaborating on an orderly transition, while Sangamo explores options to advance the program, including seeking a new collaboration partner.

The Phase 1/2 PRECIZN-1 study of investigational SAR445136 is expected to be completed as planned, with final patients in study expected to be dosed in third quarter of 2022. The preliminary Phase 1/2 clinical data for the autologous sickle cell treatment are encouraging.

Sangamo said it remains committed to progressing this program and believe SAR445136 has the potential to relieve people living with sickle cell disease of some of their most challenging symptoms.

Sanofi notified Sangamo of its termination for convenience on December 30, 2021. Sangamo expects that Sanofi will continue to pay the costs of the Phase 1/2 PRECIZN-1 study until the termination date of June 28, 2022, as contemplated by the Collaboration Agreement.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Integrated energy company Chevron reported Friday that profit for the fourth quarter increased 25 percent from last year, reflecting 17 percent revenue growth amid higher realizations and higher margins on refined product sales. Adjusted earnings per share missed analysts' estimates, while quarterly revenues topped it. Reno, Nevada-based ZLINE Kitchen and Bath has expanded its recall of gas ranges citing serious risk of injury or death from carbon monoxide poisoning, the U.S. Consumer Product Safety Commission announced. The recall now includes about 30,000 units of ZLINE gas ranges, including about 28,000 units... The Food and Drug Administration's independent advisory committee unanimously recommended replacing the current original COVID vaccines used in the U.S. for primary shots with new bivalent omicron shots authorized as boosters, reports said. The committee also considered the proposal for annual COVID vaccination, however, didn't vote on it.
Follow RTT